Astrana Health, Inc. (ASTH) SEC Filings & Earnings Calls
EquiReason read 21 Astrana Health, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-23 — Astrana Health disclosed a material cybersecurity incident involving social engineering and unauthorized data access; investigation ongoing, potential impact on sensitive data and .
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.1B
- P/E TTM
- 45.1
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Sep 20268-K · 1.05Astrana Health disclosed a material cybersecurity incident involving social engineering and unauthorized data access; investigation ongoing, potential impact on sensitive data and operations.open
Risks flagged
Cybersecurity incident may lead to regulatory fines, litigation, reputational damage, and operational disruption.
“Company has determined that the incident is material... unable to estimate the full potential impact... legal, regulatory and notification-related matters.”
15 Sep 20268-K · 7.01Updated corporate investor presentation with FY2026E Adj. EBITDA guidance midpoint of $267.5M, 36.3% revenue CAGR, 6.8% margin; 1.5M patients in VBC; 81% full-risk capitation.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA · FY2026E | $268M | |
| Revenue CAGR · FY2022A-FY2026E | 36.3% | |
| Adjusted EBITDA margin · FY2026E | 6.8% | |
| Patients in value-based arrangements · Q2 2026 | 1,500,000 | |
| Care Partners members · Care Partners · Q2 2026 | 1,200,000 | |
| Full-risk capitation revenue percentage · Q2 2026 | 81.0% | |
| G&A improvement · Q2 2026 vs Q2 20 | $210.00 |
Guidance
FY2026E Adj. EBITDA guidance midpoint of $267.5M; revenue CAGR 36.3% FY2022A-FY2026E; Adj. EBITDA margin 6.8%
Company reaffirms strong growth trajectory with 36.3% revenue CAGR and 6.8% Adj. EBITDA margin, supported by membership growth and operating leverage.
Risks flagged
Forward-looking statements subject to risks; material weakness in internal control over financial reporting mentioned.
“Material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakness in a timely manner.”
10 Aug 202610-QRevenue $973M (+49% y/y); Adjusted EBITDA $69M (+43% y/y); Net income attributable to Astrana Health, Inc. $20M (+109% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $973M | +49% y/y |
| Adjusted EBITDA · Q2-2026 | $69M | +43% y/y |
| Net income attributable to Astrana Health, Inc. · Q2-2026 | $20M | +109% y/y |
| Managed patients · 2026-06-30 | 1,500,000 | +50% y/y |
| Risk-bearing organizations · 2026-06-30 | 29 | +38% y/y |
| Cost of services, excluding depreciation and amortization · Q2-2026 | $868M | +51% y/y |
| Interest expense · Q2-2026 | $16M | +117% y/y |
Risks flagged
Increased leverage from acquisition
“Interest expense for the three months ended June 30, 2026 was $16.0 million, as compared to $7.4 million for the same period in 2025, an increase of $8.6 million or 117%. The increase in interest expense was primarily due to the increased borrowings under the Second Amended and Restated Credit Facility to finance the Prospect acquisition.” · word for word
Legal contingency
“Other loss for the three months ended June 30, 2026 was $2.3 million, as compared to other income of $1.1 million for the same period in 2025, a decrease in other income of $3.4 million or 303%. The decrease in other income was primarily due to accrual for a non-routine legal matter.” · word for word
6 Aug 20268-K · 2.02, 7.01Total revenue $972M (+49% y/y); Net income $18M (+81% y/y); Adjusted EBITDA $69M (+43% y/y); Guidance: FY2026 adjusted EBITDA guidance raised to $255-280M (from prior); revenue reaffirmed $3.8-4.1B; FCF reaffirmed $105-132.5Mearningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q2-2026 | $973M | +49% y/y |
| Net income · Q2-2026 | $19M | +81% y/y |
| Adjusted EBITDA · Q2-2026 | $69M | +43% y/y |
| Free cash flow · H1-2026 | $93M | |
| Care Partners revenue · Care Partners · Q2-2026 | $933M | +48% y/y |
| Adjusted EPS - diluted · Q2-2026 | $0.80 | +45% y/y |
| Net cash provided by operating activities · H1-2026 | $101M |
Guidance
FY2026 adjusted EBITDA guidance raised to $255-280M (from prior); revenue reaffirmed $3.8-4.1B; FCF reaffirmed $105-132.5M
Raised adjusted EBITDA guidance for FY2026; reaffirmed revenue and FCF guidance; strong Q2 beat.
13 Jul 20268-K · 7.01Gross shared savings $120M; Medicare beneficiaries served 100,000; Total revenue (FY2025) $3.18Bopen
Figures in the filing · each found in the filing text
| Gross shared savings · ACO · FY2024 | $120M | |
| Medicare beneficiaries served · ACO · FY2024 | 100,000 | |
| Total revenue (FY2025) · FY2025 | $3.18B | |
| Adjusted EBITDA (FY2025) · FY2025 | $205M |
12 May 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Loss of a key medical officer may affect clinical strategy.
“Resignation of Chief Medical Officer.”
8 May 202610-QTotal Revenue $965M (+56% y/y); Net Income Attributable to Astrana Health, Inc. $14M (+116% y/y); Adjusted EBITDA $66M (+82% y/y)open
Figures in the filing · each found in the filing text
| Total Revenue · Q1-2026 | $965M | +56% y/y |
| Net Income Attributable to Astrana Health, Inc. · Q1-2026 | $14M | +116% y/y |
| Adjusted EBITDA · Q1-2026 | $66M | +82% y/y |
| Capitation Revenue, net · Q1-2026 | $893M | +53% y/y |
| Managed Patients · 2026-03-31 | 1,550,000 | +55% y/y |
| Risk-Bearing Organizations · 2026-03-31 | 29 | +45% y/y |
| Cost of Services, excluding D&A · Q1-2026 | $859M | +57% y/y |
| General and Administrative Expenses · Q1-2026 | $62M | +41% y/y |
| Interest Expense · Q1-2026 | $16M | +120% y/y |
| Outstanding Borrowings · 2026-03-31 | $1.04B | +152% y/y |
Guidance
No explicit quantitative guidance provided, but management expresses positive outlook on 2027 Medicare Advantage rates and risk adjustment stability.
Risks flagged
Integration and Leverage Risk from Prospect Acquisition
“Interest expense for the three months ended March 31, 2026, was $16.1 million, as compared to $7.3 million for the same period in 2025, an increase of $8.8 million or 120%. The increase in interest expense was primarily due to the increased borrowings under the Second Amended and Restated Credit Facility to finance the Prospect acquisition.” · word for word
Concentration Risk in Medicare Advantage
“Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to deliver high-quality, cost-effective care.” · word for word
7 May 20268-K · 2.02, 7.01Total revenue $965M (+56% y/y); Adjusted EBITDA $66M (+82% y/y); Free cash flow $64M (+372% y/y)earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $965M | +56% y/y |
| Adjusted EBITDA · Q1-2026 | $66M | +82% y/y |
| Free cash flow · Q1-2026 | $64M | +372% y/y |
17 Apr 2026DEF 14ATotal Revenue $3.18B (+56% y/y); Net Income Attributable to Astrana Health, Inc. $22M; Adjusted EBITDA $205M (+21% y/y)open
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $3.18B | +56% y/y |
| Net Income Attributable to Astrana Health, Inc. · FY2025 | $23M | |
| Adjusted EBITDA · FY2025 | $205M | +21% y/y |
| Care Partners Revenue · Care Partners · FY2025 | $3.02B | +55% y/y |
| Managed Patients · 2025-12-31 | 1,600,000 | |
| Earnings Per Share - Diluted · FY2025 | $0.46 |
Guidance
No explicit forward guidance, but compensation metrics (revenue, Adjusted EBITDA) and positive commentary on 2027 Medicare Advantage rates suggest management is optimistic.
Risks flagged
Integration and Leverage Risk from Prospect Acquisition
“Interest expense 50.0 (from reconciliation table), up from 33.1 in 2024, reflecting increased debt to finance the Prospect acquisition.”
Concentration Risk in Medicare Advantage
“Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to deliver high-quality, cost-effective care.”
30 Mar 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Integration risk from acquisition of multiple entities and assets.
“Acquisition of multiple entities and assets may pose integration challenges.”
12 Mar 202610-KRevenue $3.18B (+56% y/y); Net income $24M (-52% y/y); Adjusted EBITDA $205M (+21% y/y)open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $3.18B | +56% y/y |
| Net income · FY2025 | $24M | -52% y/y |
| Adjusted EBITDA · FY2025 | $205M | +21% y/y |
| Adjusted EBITDA margin · FY2025 | 6.0% | |
| Free cash flow · FY2025 | $104M | +137% y/y |
| Operating cash flow · FY2025 | $115M | +120% y/y |
| Cash and cash equivalents · FY2025 | $430M | |
| Total debt · FY2025 | $1.05B | |
| Adjusted EPS - diluted · FY2025 | $2.20 | +13% y/y |
Risks flagged
High Indebtedness from Acquisition
“Financing the Prospect Acquisition resulted in an increase in our indebtedness, which could adversely affect us, including by decreasing our business flexibility and increasing our interest expense.” · word for word
Integration Risk
“Any difficulties integrating Prospect’s operations could disrupt or have a material adverse effect on our current plans, business, or results of operations.” · word for word
Medicaid Policy Risk
“The OBBBA could result in reductions in our patient population and managed care enrollees that we serve across our federal healthcare program lines of business.”
Material Weakness in Internal Controls
“We identified a material weakness in our internal control over financial reporting related to our accounting for business combinations.” · word for word
Bankruptcy of Prospect Seller Entities
“On July 7, 2025, those entities related to Prospect that sold assets to us in the Prospect Acquisition filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code.” · word for word
4 Mar 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
Expected material weakness in internal control over financial reporting related to acquisition and purchase accounting processes.
“the expected material weakness in internal control over financial reporting, the consistency of the financial statements in the 2025 Form 10-K with the financial information in the Company's earnings release” · word for word
2 Mar 20268-K · 2.02, 7.01, 8.01Released earnings results and quarterly financials; issued a Regulation FD disclosure (forward guidance or material update)earningsopen
Risks flagged
Material weakness in internal controls over financial reporting related to acquisition and purchase accounting processes.
“The Company anticipates reporting a material weakness in the Company's internal control over financial reporting, which is expected to relate to, but may not be limited to, the Company's acquisition and purchase accounting processes.” · word for word
12 Jan 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
No new risks identified; standard forward-looking statements.
“Standard risk factors in forward-looking statements.”
10 Nov 202510-QAstrana Health reported Q3 2025 revenue up 100% YoY to $956M, but net income attributable to the company collapsed 98% YoY to $0.4M due to acquisition costs and higher interest expense.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $956M | +100% y/y |
| Net income attributable to Astrana Health, Inc. · Q3-2025 | $373000.00 | -98% y/y |
| Adjusted EBITDA · Q3-2025 | $68M | +52% y/y |
| Managed patients · Q3-2025 | 1,600,000 | +60% y/y |
| Capitation revenue, net · Care Partners · Q3-2025 | $863M | +100% y/y |
| Cost of services, excluding depreciation and amortization · Q3-2025 | $859M | +112% y/y |
| Interest expense · Q3-2025 | $18M | +100% y/y |
| Outstanding borrowings · Q3-2025 | $1.06B | +146% y/y |
Risks flagged
Medicaid policy risk from OBBBA
“The effect of these changes could result in reductions in our patient population and managed care enrollees that we serve across our federal healthcare program lines of business due to, among other things, more stringent eligibility requirements such as the imposition of work or community service requirements, and copayments on many services, limitation of M” · word for word
Bankruptcy of Prospect seller entities
“On July 7, 2025, those entities related to Prospect that sold assets to us in the Prospect Acquisition (the 'Prospect PhysicianCo Entities') filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code, the effect of which could result in their breach or noncompliance with certain contractual obligations under the asset sale transaction, inc” · word for word
High leverage and interest expense
“Our outstanding borrowings increased to, as of September 30, 2025, $1,064.2 million on the Second Amended and Restated Credit Facility from $432.0 million borrowed under the facility as of September 30, 2024.” · word for word
6 Nov 20258-K · 2.02, 7.01Total revenue $956M (+100% y/y); Adjusted EBITDA $68M (+52% y/y); Care Partners revenue $898M (+97% y/y); Guidance: Full-year 2025 revenue $3.1-3.18B, adjusted EBITDA $200-210Mearningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $956M | +100% y/y |
| Adjusted EBITDA · Q3-2025 | $69M | +52% y/y |
| Care Partners revenue · Care Partners · Q3-2025 | $898M | +97% y/y |
| Net income attributable to Astrana · Q3-2025 | $400000.00 |
Guidance
Full-year 2025 revenue $3.1-3.18B, adjusted EBITDA $200-210M
Updated guidance reflects acquisition impact and contract timing; underlying trends remain strong.
Risks flagged
Full-risk contract delays may impact revenue timing; guidance updated to reflect this.
“Updates full-year 2025 guidance to account for full-risk contract delays unrelated to core performance” · word for word
Astrana Health, Inc. — questions
- What did Astrana Health, Inc. file recently?
- 21 SEC filings in the last 12 months. Latest: 8-K on 2026-09-23 — Astrana Health disclosed a material cybersecurity incident involving social engineering and unauthorized data access; investigation ongoing, potential impact on sensitive data and operations.
Every figure on this page comes from Astrana Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.